Acrivon Therapeutics : Submission of Matters to a Vote of Security Holders Form 8 K
June 21, 2024 at 11:03 am
Share
Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 20, 2024, Acrivon Therapeutics, Inc. (the "Company") held its 2024 annual meeting of stockholders (the "Annual Meeting"). At the Annual Meeting, a quorum of 27,422,027 shares of the Company's common stock, or 88.81% of the outstanding shares of common stock entitled to vote as of the record date of April 22, 2024, were present or represented by proxy.
Two items of business were acted upon by the stockholders at the Annual Meeting. The final results for the votes regarding each proposal are set forth below.
Proposal One: Election of Kristina Masson, Ph.D., M.B.A; Sharon Shacham, Ph.D., M.B.A.; and Ivana Magovčević-Liebisch, Ph.D., J.D. as Class II Directors.
Kristina Masson, Ph.D., M.B.A; Sharon Shacham, Ph.D., M.B.A.; and Ivana Magovčević-Liebisch, Ph.D., J.D were each elected to serve as a Class II director to hold office until the Company's 2027 Annual Meeting of Stockholders and until the election and qualification of his successor. Votes were cast as follows:
For
Withheld
Broker Non-Votes
Kristina Masson, Ph.D., M.B.A.
24,563,469
109,386
2,749,172
Sharon Shacham, Ph.D., M.B.A.
23,268,783
1,466,015
2,687,229
Ivana Magovčević-Liebisch, Ph.D., J.D.
24,498,933
237,318
2,685,776
Proposal Two: Ratification of Appointment of Independent Registered Public Accounting Firm. The stockholders ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 by the following vote:
For
Against
Abstain
Broker Non-Votes
27,405,683
6,036
10,308
-
Attachments
Original Link
Permalink
Disclaimer
Acrivon Therapeutics Inc. published this content on
21 June 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
21 June 2024 10:02:08 UTC.
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead candidate, ACR-368, is a selective small molecule inhibitor which targets CHK1 and CHK2 at sub single-digit nM and single-digit nM potency in intact cells, respectively, in a potentially registrational Phase 2 trial across multiple solid tumor types. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy and therefore substantially improve the clinical overall response rate (ORR) and has the potential to enable expedited drug development. Its preclinical program, ACR-2316, is advancing in IND-enabling studies. It is a novel, dual WEE1 and PKMYT1 inhibitor small molecule development candidate.